| Metric | Value ($ M) | vs Q2 FY25 |
|---|---|---|
| Revenue | 1.45 | 13.2% |
| Total Income | 1.45 | 13.2% |
| Expenditure | 3.33 | 8.5% |
| PBT | -2.73 | 95.0% |
| Net Profit | -2.73 | 95.0% |
| OPM | — | |
| NPM | — | |
| EPS | -0.61 | 96.8% |
Callan JMB Announces Q3 2025 Results; Revenue at $1.4 Million
04 May 2026 · 4 May, 7:11 am
Summary
Callan JMB reported revenues of $1.4 million for the third quarter ended September 30, 2025, and $4.6 million for the nine months ended September 30, 2025. The year-over-year revenue decrease was attributed to the seasonal decline in demand for emergency preparedness services. The company expanded into the food sampling sector and entered an agreement to install oral drug delivery equipment at its Texas facility. Callan JMB also established a subsidiary in India for pharmaceutical storage and distribution.
Key Highlights
- 1
Callan JMB's revenues for the third quarter ended September 30, 2025, were $1.4 million.
- 2
Revenues for the nine months ended September 30, 2025, reached $4.6 million.
- 3
The company expanded its compliance-driven logistics platform into the food sampling sector.
- 4
Callan JMB entered into an agreement to install oral drug delivery equipment at its Texas facility.
- 5
A subsidiary was established in India to advance plans for a temperature-controlled pharmaceutical storage and distribution warehouse.
- 6
The company's contract with the City of Chicago was extended through June 2026, including an increase in funding to $9.1 million.
- 7
The Sentry Monitoring System Technology was upgraded with Sentry 4 for Mobile Temperature Monitoring.
Management Comments
Wayne Williams
Callan JMB continues to execute with excellence across our core business lines, while also leveraging our key competencies to expand into target growth areas. We recently launched into the food sampling sector, as a natural extension of our core capabilities and part of our multi-variant strategic growth initiatives. We have also made progress to support the onshoring of logistics operations to the U.S. in the future, particularly for international companies operating in the pharmaceutical space. This month, we entered a preliminary agreement with a maker of an innovative drug delivery system to install its manufacturing equipment in our cGMP facility in Texas, while we negotiate further operational agreements. In July, we formed Callan JMB Services (India) Private Limited, with a planned temperature-controlled warehouse for storage and distribution of pharmaceuticals at all temperature ranges. Our emergency preparedness business continues to perform well, with the City of Chicago extending our contract through June 2026 with an additional $1.5 million in funding, bringing the total contract value to $9.1 million and reinforcing our eight-year partnership. Finally, we enhanced our technology platform by upgrading our proprietary Sentry Monitoring System to version 4.0, transitioning from Java to HTML5 to provide healthcare facilities and emergency management agencies with seamless, device-agnostic access to critical temperature monitoring capabilities. These advancements reflect our commitment to delivering innovative solutions that meet evolving customer needs. As we close out 2025, we are focused on driving sustainable growth across our pharmaceutical logistics, emergency preparedness, and specialty distribution operations while pursuing strategic opportunities in complementary high-growth markets that build on our established skill set
Informational and educational content only. Not investment advice.